This trial aims to find out if combining nivolumab (Opdivo) and ipilimumab (Yervoy) with chemotherapy in patients with advanced non-small cell lung cancer is more effective than only treating with chemotherapy. The main outcome that will be measured is overall survival.
The details
There are a number of different treatment options for non-small cell lung cancer (NSCLC). Often a number of different treatments are used one after another. Chemotherapy is a common first type of treatment for NSCLC. It is not known if adding nivolumab and ipilimumab to chemotherapy treatment will be more effective than just using chemotherapy as a first-line treatment.
This trial aims to find out if combining nivolumab (Opdivo) and ipilimumab (Yervoy) with chemotherapy in patients with advanced NSCLC is more effective than only treating with chemotherapy. The main outcome that will be measured is how long the patients survive.
Who are they looking for?
This trial is recruiting 700 patients. Patients must not have had any other anti-cancer treatment. Patients cannot have EGFR mutations. Patients who have untreated brain tumors or spinal cord tumors cannot be in the trial.
How will it work
Patients in this study will be split into two groups. One group will only receive chemotherapy treatment. The chemotherapy can be any combination of the following drugs: carboplatin, paclitaxel, pemetrexed, and cisplatin. The second group will receive the same treatment with chemotherapy, but will also be treated with nivolumab and ipilimumab.
Patients will be followed up for 25 months. Response to treatment and survival will be the main outcomes measured.
